Januvia (sitagliptin) - Merck (MSD)
Effect of sitagliptin combined with basal insulin therapy during the perioperative period of total joint replacement in patients with non-insulin-dependent type 2 diabetes on blood glucose control: A prospective randomized controlled study (ChiCTR) - Oct 16, 2026 - P=N/A | N=160 | Not yet recruiting | Sponsor: West China Hospital; Sichuan University, West China Hospital 
New trial • Diabetes • Hypoglycemia • Immunology • Metabolic Disorders • Orthopedics • Osteoarthritis • Rheumatology • Type 2 Diabetes Mellitus
https://www.chictr.org.cn/showproj.html?proj=323145
 
Oct 16, 2026
 
Prev Next